Inovio Pharmaceuticals’ (INO) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research note published on Friday,Benzinga reports. They currently have a $18.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. Royal Bank of Canada lowered their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. HC Wainwright lowered their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. Finally, Oppenheimer lowered their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.80.

Inovio Pharmaceuticals Trading Down 5.3 %

INO opened at $1.98 on Friday. The stock has a market capitalization of $51.68 million, a P/E ratio of -0.95 and a beta of 0.84. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The firm’s fifty day simple moving average is $3.42 and its 200 day simple moving average is $6.10.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in INO. Bank of New York Mellon Corp bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $661,000. Dimensional Fund Advisors LP bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $605,000. Wellington Management Group LLP acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth approximately $379,000. State Street Corp increased its position in Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after purchasing an additional 51,414 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Inovio Pharmaceuticals by 6.7% during the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 38,833 shares in the last quarter. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.